28
January 2025
ImmuPharma
PLC
("ImmuPharma" or the "Company")
Response to Share Price
Movement
ImmuPharma PLC (LSE:IMM), the
specialist drug discovery and development company, notes the recent
movements in its share price.
As announced on 9 January 2025, the
Company has made innovative groundbreaking advancements in its
preclinical research program focused on P140 and the pathogenesis
of autoimmune diseases. This new discovery, conducted by the
Company's R&D subsidiary ImmuPharma Biotech, has yielded data
that provides novel insights into autoimmune disease
mechanisms. Through this research, the
Company is making a significant step towards personalised medicine
in SLE and other autoimmune diseases.
(Link: https://www.immupharma.co.uk/news/)
The ImmuPharma team also attended
the JP Morgan and Biotech Showcase healthcare conferences earlier
this month.
Attending both meetings gave the
ImmuPharma team the opportunity to continue positive discussions
with a number of global BioPharma companies, that have already
expressed an interest in P140 and its unique approach to treating
autoimmune diseases.
ImmuPharma is not aware of any
further material commercial or operational reason for the
significant share price movements, however, the Company will
continue to update the market on developments, both commercially
and scientifically, when appropriate, over the next
period.
End
|
For further information please
contact:
|
ImmuPharma PLC (www.immupharma.co.uk)
Tim McCarthy, Chief Executive
Officer
Lisa Baderoon, Head of Investor
Relations
|
+44 (0) 207 206 2650
+ 44 (0) 7721 413496
|
|
|
|
|
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Stanford Capital Partners (Joint Broker)
Patrick Claridge, Bob
Pountney
SI
Capital (Joint Broker)
Nick Emerson
|
+44 (0) 203
368
3550
+44 (0) 20 3650 3650
+44 (0) 1483 413500
|
|
|
|
|
Notes to Editors
About ImmuPharma
PLC
ImmuPharma PLC (LSE AIM: IMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases and anti-infectives.
The lead program, P140, is a unique non-immunosuppressive peptide
for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP
(Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical
models suggest therapeutic activity for many other autoimmune
diseases.
For additional information about
ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity
Identifier) code : 213800VZKGHXC7VUS895.
